David Planchard
Impact in
- Oncology top 0.05%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 259
- Lung Cancer Diagnosis and Treatment 54
- Oncology 288
- Lung Cancer Research Studies 111
- Cancer Immunotherapy and Biomarkers 106
- Colorectal Cancer Treatments and Studies 64
- HER2/EGFR in Cancer Research 33
- Co-authors
- Benjamin Besse (163 shared papers)Egbert F. Smit (22 shared papers)Jean‐Charles Soria (57 shared papers)Solange Peters (9 shared papers)Silvia Novello (13 shared papers)Tony Mok (4 shared papers)Keith M. Kerr (3 shared papers)Julien Mazières (38 shared papers)
- Journals
- Annals of Oncology (100 papers)Journal of Clinical Oncology (60 papers)Journal of Thoracic Oncology (40 papers)Lung Cancer (18 papers)Cancer Research (13 papers)
- Partner nations
- FranceUnited StatesSpain
In The Last Decade
David Planchard
411 papers receiving 16.2k citations
David Planchard's Hit Papers
Peers
Comparison fields: 5 of 134
- Oncology 11.0k
- Pulmonary and Respiratory Medicine 10.0k
- Cancer Research 3.4k
- Pathology and Forensic Medicine 1.3k
- Molecular Biology 4.6k
Countries citing papers authored by David Planchard
This map shows the geographic impact of David Planchard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Planchard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Planchard more than expected).
Fields of papers citing papers by David Planchard
This network shows the impact of papers produced by David Planchard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Planchard. The network helps show where David Planchard may publish in the future.
Co-authors
The 25 scholars most cited alongside David Planchard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 431 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 1586 |
| 2 | AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 1585 |
| 3 | Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial Hit paper breakdown → | 2017 | 948 |
| 4 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 712 |
| 5 | Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial Hit paper breakdown → | 2016 | 612 |
| 6 | Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 370 |
| 7 | Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial Hit paper breakdown → | 2016 | 334 |
| 8 | 2011 | 325 | |
| 9 | 2011 | 308 | |
| 10 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC Hit paper breakdown → | 2019 | 305 |
| 11 | Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 286 |
| 12 | 2016 | 264 | |
| 13 | 2015 | 255 | |
| 14 | 2015 | 248 | |
| 15 | 2017 | 244 | |
| 16 | 2013 | 244 | |
| 17 | 2019 | 238 | |
| 18 | 2013 | 221 | |
| 19 | 1990 | 175 | |
| 20 | 2021 | 141 |
About David Planchard
David Planchard is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Epidemiology, having authored 431 papers that have together received 16.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (259 papers), Lung Cancer Research Studies (111 papers), Cancer Immunotherapy and Biomarkers (106 papers), Colorectal Cancer Treatments and Studies (64 papers), Cancer Genomics and Diagnostics (55 papers), Lung Cancer Diagnosis and Treatment (54 papers), HER2/EGFR in Cancer Research (33 papers) and Neuroendocrine Tumor Research Advances (27 papers). The work is most often cited by research in Oncology (11.0k citations), Pulmonary and Respiratory Medicine (10.0k citations), Cancer Research (3.4k citations), Pathology and Forensic Medicine (1.3k citations) and Molecular Biology (4.6k citations). David Planchard has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Benjamin Besse, Egbert F. Smit, Jean‐Charles Soria, Solange Peters, Silvia Novello, Tony Mok, Keith M. Kerr, Julien Mazières, Matthew D. Hellmann and Martin Reck. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.